Behavioral and Clinical Surveillance Branch
To guide HIV prevention and care by identifying, monitoring, and reporting the drivers of the HIV epidemic.
The Behavioral and Clinical Surveillance Branch manages the following projects:
The Medical Monitoring Project (MMP) is a national population-based surveillance system that collects information on clinical outcomes and behaviors of HIV-diagnosed adults in the United States. Collection of data from interviews with people with HIV provides information on behaviors that may facilitate: HIV transmission; access to, use of, and barriers to HIV-related secondary prevention services; utilization of HIV-related medical services; adherence to drug regimens; and linkage to and engagement in care. Through abstraction of medical records, MMP also provides information on clinical conditions that occur in HIV-infected persons as a result of their disease or the medications they take, receipt of HIV care and support services, and the quality of these services.
In 2003, CDC created National HIV Behavioral Surveillance (NHBS) to conduct behavioral surveillance among persons at high risk for HIV infection. Surveillance is conducted in rotating, annual cycles in three different populations at increased risk for HIV: men who have sex with men (MSM), persons who inject drugs (PWID), and heterosexually active persons at increased risk for HIV infection (HET). Before each NHBS cycle, formative assessment is conducted to learn more about each local population and to inform operational procedures. Trained interviewers in all NHBS project areas use a standardized, anonymous questionnaire to collect information on HIV-related risk behaviors, HIV testing, and the use of HIV prevention services. HIV testing is offered to all participants. During each cycle, a minimum of 500 eligible persons from each participating project area are interviewed and offered HIV testing.
The Injection Drug Use Surveillance Project (IDU-SP) is an HIV status-neutral, bio-behavioral surveillance activity conducted in collaboration with syringe services programs (SSPs) among people who inject drugs (PWID) and their peers who may be at high risk for injection drug use.
Participating syringe services programs (SSPs) are selected from the top 25 states with the highest overdose death burden and to ensure diversity based on region, urbanicity, syringe access policy, and affiliation with health departments. At each of the selected SSPs, clients of the program are systematically approached and invited to participate in IDU-SP. Project participants are then asked to recruit others they know who use drugs via injecting and non-injecting routes. The IDU-SP was designed to provide valuable information to each participating SSP and to reach deeper into the networks of persons who use drugs to understand drug use related risks and access to services. Data from this surveillance project will be used to inform planning and evaluation of prevention programs that aim to reduce injection-related adverse health outcomes, to calculate population size estimates of PWID in a community, to address social determinants of health related to injection drug use, and to establish an ongoing surveillance of injection drug use and associated risks. All IDU-SP participants are offered HIV and HCV testing, as well as referrals to care and social services upon completion of the survey.
This section provides information on funding opportunities led by the Behavioral and Clinical Surveillance Branch
- Notice of Funding Opportunity PS22-2211: Enhanced Surveillance of Persons with Early and Late HIV Diagnosis
This NOFO is a re-announcement of PS22-2202. The purpose of this NOFO is to improve understanding of barriers and gaps in HIV prevention services that may lead to continued HIV transmission or delayed diagnosis of HIV. This NOFO will support enhanced surveillance of people diagnosed with HIV during the earliest and latest stages of infection (i.e., stages 0 and 3, respectively) to understand recent experiences with HIV prevention and testing services, as well as the system- and individual-level barriers that led to these failures in early diagnosis and prevention. Recipients of this NOFO will identify, locate, and recruit all persons diagnosed in the past year with stage 0 or stage 3 infection in their jurisdiction for participation in behavioral interviews conducted by a CDC contractor.
- PS22-2201: National HIV Behavioral Surveillance (NHBS)
CDC has published the Notice of Funding Opportunity PS22-2201, National HIV Behavioral Surveillance (NHBS). The purpose of NHBS is to support ongoing national bio-behavioral surveillance to monitor HIV-related behaviors, detect changes over time in HIV risk behaviors among populations overburdened by HIV infections, and to inform and evaluate HIV prevention activities. This NOFO also aims to fill gaps in knowledge regarding HIV prevention priorities among populations in geographic areas where current data are limited.